Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer

Cancer Research

Volumn 63, Issue 6, 2003, Pages 1389-1397

  Connolly, Denise C ^a   Bao, Rudi ^a,d   Nikitin, Alexander Yu ^b   Stephens, Kasie C ^a   Poole, Timothy W ^a,e   Hua, Xiang ^a   Harris, Skye S ^a   Vanderhyden, Barbara C ^c   Hamilton, Thomas C ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d Novartis Oncology Pharmacology   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; CYTOKERATIN 19; CYTOKERATIN 8; INHIBIN; VIRUS T ANTIGEN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CANCER GROWTH; CANCER RESEARCH; CARCINOGENICITY; CELL LINE; CONTROLLED STUDY; CYST; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; GRANULOSA CELL TUMOR; HISTOLOGY; IMMUNE DEFICIENCY; IMPLANTATION; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OMENTUM; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SIMIAN VIRUS 40; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CHIMERA; DISEASE MODELS, ANIMAL; EPITHELIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OVARIAN NEOPLASMS; PREGNANCY; PROMOTER REGIONS (GENETICS); RECEPTORS, PEPTIDE; REGULATORY SEQUENCES, NUCLEIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0037444396     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Greenlee, R. T., Hill-Harmon, M. B., Murray, T., and Thun, M. Cancer statistics, 2001. CA Cancer J. Clin., 51: 15-36, 2001.
2. Salazar, H., Godwin, A. K., Daly, M. B., Laub, P. B., Hogan, W. M., Rosenblum, N., Boente, M. P., Lynch, H. T., and Hamilton, T. C. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J. Natl. Cancer Inst., 88: 1810-1820, 1996.
3. Castrillon, D. H., and DePinho, R. A. Modeling prostate cancer in the mouse. Adv. Cancer Res., 82: 187-204, 2001.
4. Huss, W. J., Maddison, L. A., and Greenberg, N. M. Autochthonous mouse models for prostate cancer: past, present and future. Semin. Cancer Biol., 11: 245-260, 2001.
5. Blackshear, P. E. Genetically engineered rodent models of mammary gland carcinogenesis: an overview. Toxicol. Pathol., 29: 105-116, 2001.
6. Green, J. E., Shibata, M. A., Yoshidome, K., Liu, M. L., Jorcyk, C., Anver, M. R., Wigginton, J., Wiltrout, R., Shibata, E., Kaczmarczyk, S., Wang, W., Liu, Z. Y., Calvo, A., and Couldrey, C. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene, 19: 1020-1027, 2000.
7. Moser, A. R., Luongo, C., Gould, K. A., McNeley, M. K., Shoemaker, A. R., and Dove, W. F. ApcMin: a mouse model for intestinal and mammary tumorigenesis. Eur. J. Cancer, 31A: 1061-1064, 1995.
8. Kobaek-Larsen, M., Thorup, I., Diederichsen, A., Fenger, C., and Hoitinga, M. R. Review of colorectal cancer and its metastases in rodent models: comparative aspects with those in humans. Comp. Med., 50: 16-26, 2000.
9. Tuveson, D. A., and Jacks, T. Modeling human lung cancer in mice: similarities and shortcomings. Oncogene, 18: 5318-5324, 1999.
10. Holland, E. C. Brain tumor animal models: importance and progress. Curr. Opin. Oncol., 13: 143-147, 2001.
11. Chin, L. Modeling malignant melanoma in mice: pathogenesis and maintenance. Oncogene, 18: 5304-5310, 1999.
12. Feeley, K. M., and Wells, M. Precursor lesions of ovarian epithelial malignancy. Histopathology, 38: 87-95, 2001.
13. Powell, D. E., Puls, L., and van Nagell, J., Jr. Current concepts in epithelial ovarian tumors: does benign to malignant transformation occur? Hum. Pathol., 23: 846-847, 1992.
14. Puls, L. E., Powell, D. E., DePriest, P. D., Gallion, H. H., Hunter, J. E., Kryscio, R. J., and van Nagell, J. R., Jr. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol. Oncol., 47: 53-57, 1992.
15. Resta, L., Russo, S., Colucci, G. A., and Prat, J. Morphologic precursors of ovarian epithelial tumors. Obstet. Gynecol., 82: 181-186, 1993.
16. Scully, R. E. Pathology of ovarian cancer precursors. J. Cell. Biochem. Suppl., 23: 208-218, 1995.
17. Auersperg, N., Wong, A. S., Choi, K. C., Kang, S. K., and Leung, P. C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev., 22: 255-288, 2001.
18. Josso, N., di Clemente, N., and Gouedard, L. Anti-Mullerian hormone and its receptors. Mol. Cell. Endocrinol., 179: 25-32, 2001.
19. Teixeira, J., Maheswaran, S., and Donahoe, P. K. Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr. Rev., 22: 657-674, 2001.
20. Hanahan, D. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature (Lond.), 315: 115-122, 1985.
21. Roby, K. F., Taylor, C. C., Sweetwood, J. P., Cheng, Y., Pace, J. L., Tawfik, O., Persons, D. L., Smith, P. G., and Terranova, P. F. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis (Lond.), 21: 585-591, 2000.
22. Connolly, D. C., Toutenhoofd, S. L., and Maihle, N. J. Tyrosine kinase activity may be necessary but is not sufficient for c-erbB 1-mediated tissue-specific tumorigenicity. J. Virol., 68: 6804-6810, 1994.
23. Teixeira, J., Kehas, D. J., Antun, R., and Donahoe, P. K. Transcriptional regulation of the rat Mullerian inhibiting substance type II receptor in rodent Leydig cells. Proc. Natl. Acad. Sci. USA, 96: 13831-13838, 1999.
24. Dubeau, L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol. Oncol., 72: 437-442, 1999.
25. MacLaughlin, D. T., Teixeira, J., and Donahoe, P. K. Perspective: reproductive tract development-new discoveries and future directions. Endocrinology, 142: 2167-2172, 2001.
26. di Clemente, N., Wilson, C., Faure, E., Boussin, L., Carmillo, P., Tizard, R., Picard, J. Y., Vigier, B., Josso, N., and Cate, R. Cloning, expression, and alternative splicing of the receptor for anti-Mullerian hormone. Mol. Endocrinol., 8: 1006-1020, 1994.
27. Baarends, W. M., Uilenbroek, J, T., Kramer, P., Hoogerbrugge, J. W., van Leeuwen, E. C., Themmen, A. P., and Grootegoed, J. A. Anti-mullerian hormone and anti-mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology, 136: 4951-4962, 1995.
28. Baarends, W. M., van Helmond, M. J., Post, M., van der Schoot, P. J., Hoogerbrugge, J. W., de Winter, J. P., Uilenbroek, J. T., Karels, B., Wilming, L. G., Meijers, J. H., and et al. A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the mullerian duct. Development (Camb.), 120: 189-197, 1994.
29. Teixeira, J., He, W. W., Shah, P. C., Morikawa, N., Lee, M. M., Catlin, E. A., Hudson, P. L., Wing, J., Maclaughlin, D. T., and Donahoe, P. K. Developmental expression of a candidate mullerian inhibiting substance type II receptor. Endocrinology, 137: 160-165, 1996.
30. Masiakos, P. T., MacLaughlin, D. T., Maheswaran, S., Teixeira, J., Fuller, A. F., Jr., Shah, P. C., Kehas, D. J., Kenneally, M. K., Dombkowski, D. M., Ha, T. U., Preffer, F. I., and Donahoe, P. K. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin. Cancer Res., 5: 3488-3499, 1999.
31. Josso, N., Racine, C., di Clemente, N., Rey, R., and Xavier, F. The role of anti-Mullerian hormone in gonadal development. Mol. Cell. Endocrinol., 145: 3-7, 1998.
32. Chen, J., Tobin, G. J., Pipas, J. M., and Van Dyke, T. T-antigen mutant activities in vivo: roles of p53 and pRB binding in tumorigenesis of the choroid plexus. Oncogene, 7: 1167-1175, 1992.
33. Maroulakou, I. G., Anver, M., Garrett, L., and Green, J. E. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc. Natl. Acad. Sci. USA, 91: 11236-11240, 1994.
34. Greenberg, N. M., DeMayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., Cunha, G. R., Donjacour, A. A., Matusik, R. J., and Rosen, J. M. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA, 92: 3439-3443, 1995.
35. Kasper, S., Sheppard, P. C., Yan, Y., Pettigrew, N., Borowsky, A. D., Prins, G. S., Dodd, J. G., Duckworth, M. L., and Matusik, R. J. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab. Investig., 78: i-xv, 1998.
36. Grippo, P. J., and Sandgren, E. P. Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model. Am. J. Pathol., 157: 805-813, 2000.
37. Chailley-Heu, B., Rambaud, C., Barlier-Mur, A. M., Galateau-Salle, F., Perret, C., Capron, F., and Lacaze-Masmonteil, T. A model of pulmonary adenocarcinoma in transgenic mice expressing the simian virus 40 T antigen driven by the rat Calbindin-D9K (CaBP9K) promoter. J. Pathol., 195: 482-489, 2001.
38. Hsu, S. Y., Lai, R. J., Finegold, M., and Hsueh, A. J. Targeted overexpression of Bcl-2 in ovaries of transgenic mice leads to decreased follicle apoptosis, enhanced folliculogenesis, and increased germ cell tumorigenesis. Endocrinology, 137: 4837-4843, 1996.
39. Dutertre, M., Gouedard, L., Xavier, F., Long, W. Q., di Clemente, N., Picard, J. Y., and Rey, R. Ovarian granulosa cell tumors express a functional membrane receptor for anti-Mullerian hormone in transgenic mice. Endocrinology, 142: 4040-4046, 2001.
40. Risma, K. A., Clay, C. M., Nett, T. M., Wagner, T., Yun, J., and Nilson, J. H. Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. Proc. Natl. Acad. Sci. USA, 92: 1322-1326, 1995.
41. Rahman, N. A., Kananen Rilianawati, K., Paukku, T., Mikola, M., Markkula, M., Hamalainen, T., and Huhtaniemi, I. T. Transgenic mouse models for gonadal tumor-igenesis. Mol. Cell. Endocrinol., 145: 167-174, 1998.
42. Godwin, A. K., Testa, J. R., Handel, L. M., Liu, Z., Vanderveer, L. A., Tracey, P. A., and Hamilton, T. C. Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J. Natl. Cancer Inst., 84: 592-601, 1992.
43. Orsulic, S., Li, Y., Soslow, R. A., Vitale-Cross, L. A., Gutkind, J. S., and Varmus, H. E. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cells (Cold Spring Harbor), 1: 53-62, 2002.